Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer

被引:179
作者
Gee, JM
Robertson, JF
Gutteridge, E
Ellis, IO
Pinder, SE
Rubini, M
Nicholson, RI
机构
[1] Univ Cardiff Wales, Welsh Sch Pharm, Tenovus Ctr Canc Res, Cardiff, Wales
[2] City Hosp Nottingham, Dept Histopathol, Nottingham, England
[3] City Hosp Nottingham, Professorial Surg Unit, Nottingham, England
[4] Univ Ferrara, Dipartimento Med Sperimentale & Diagnost, I-44100 Ferrara, Italy
关键词
D O I
10.1677/erc.1.01005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer models of acquired tamoxifen resistance, oestrogen receptor (ER)(+)/ER- de novo resistance and gene transfer studies cumulatively demonstrate the increased importance of growth factor receptor signalling, notably the epidermal growth factor receptor (EGFR)/HER2, in tamoxifen resistance. Our recent in vitro studies also suggest that EGFR signalling productively cross-talks with insulin-like growth factor receptor (IGF-1R) and, where present, activates ER on key AF-1 serine residues to facilitate acquired tamoxifen-resistant growth. This paper presents our immunohistochemical evidence that EGFR/HER2 signalling (i.e. transforming growth factor (TGF)alpha, EGFR and HER2 expression; phosphorylation of EGFR, HER2 and ERK1/2 MAP kinase) is also prominent in clinical de novo resistant and modestly increased in acquired tamoxifen-resistant states, suggesting that anti-EGFR/HER2 strategies may prove valuable treatments. Primary breast cancer samples employed were obtained for (1) patients subsequently treated with tamoxifen for advanced disease where endocrine response and survival data were available and (2) ER+ elderly patients during tamoxifen response and relapse. We also present our clinical immunohistochemical findings that IGF-1R expression, its phosphorylation on tyrosine 1316, and also phosphorylation on serine 118 of ER are not only prominent in ER+ tamoxifen-responsive disease, but are also detectable in ER+ de novo and acquired tamoxifen-resistant breast cancer, where there is evidence of EGFR/ER cross-talk. Our data suggest that agents to deplete effectively ER or IGF-1R signalling may be of value in treating ER+ de novo/acquired tamoxifen resistance in addition to tamoxifen-responsive disease in vivo. IGF-1R inhibitors may also prove valuable in ER- patients, since considerable IGF-1R signalling activity was apparent within similar to 50% of such tumours.
引用
收藏
页码:S99 / S111
页数:13
相关论文
共 55 条
[1]  
[Anonymous], P AM SOC CLIN ONCOL
[2]   HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study [J].
Arpino, G ;
Green, SJ ;
Allred, DC ;
Lew, D ;
Martino, S ;
Osborne, CK ;
Elledge, RM .
CLINICAL CANCER RESEARCH, 2004, 10 (17) :5670-5676
[3]  
Bartucci M, 2001, CANCER RES, V61, P6747
[4]  
BENZ CC, 1993, BREAST CANCER RES TR, V24, P85
[5]   Epidermal growth factor-induced nuclear factor κB activation:: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells [J].
Biswas, DK ;
Cruz, AP ;
Gansberger, E ;
Pardee, AB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (15) :8542-8547
[6]   Phosphorylation of human estrogen receptor α at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera [J].
Chen, DS ;
Washbrook, E ;
Sarwar, N ;
Bates, GJ ;
Pace, PE ;
Thirunuvakkarasu, V ;
Taylor, J ;
Epstein, RJ ;
Fuller-Pace, FV ;
Egly, JM ;
Coombes, RC ;
Ali, S .
ONCOGENE, 2002, 21 (32) :4921-4931
[7]  
Dowsett M, 2001, CANCER RES, V61, P8452
[8]  
Elledge RM, 1998, CLIN CANCER RES, V4, P7
[9]  
Ellis MJ, 2003, CANCER RES, V63, P6523
[10]  
Gee JM, 2003, BREAST CANCER RES TR, V82, pS102